Disease · MONDO_0018965
Alport syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Alport syndrome. Diseases, record MONDO_0018965. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018965
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs21
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RAMIPRIL | CHEMBL1168 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BARDOXOLONE METHYL | CHEMBL1762621 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ELX-02 | CHEMBL4297744 | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets | |
| LADEMIRSEN | CHEMBL4298087 | Oligonucleotide | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| VALSARTAN | CHEMBL1069 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| ATRASENTAN | CHEMBL9194 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BENAZEPRIL | CHEMBL838 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUVASTATIN | CHEMBL2220442 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYDROXYCHLOROQUINE | CHEMBL1535 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SPARSENTAN | CHEMBL539423 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 21
See all 21 drugsTargets94
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | 6 | Type-1 angiotensin II receptor antagonist | Phase 2 | https://conductscience.org/library/genes/185 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 2 | Angiotensin-converting enzyme inhibitor | Phase 3 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| EDNRA | Endothelin-1 receptor | 2 | Endothelin receptor ET-A antagonist | Phase 2 | https://conductscience.org/library/genes/1909 | Drugs and targets |
| MIR21 | microRNA 21 | 2 | microRNA 21 antisense inhibitor | Phase 2 | https://conductscience.org/library/genes/406991 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 2 | Mineralocorticoid receptor antagonist | Unknown | https://conductscience.org/library/genes/4306 | Drugs and targets |
| FAU | 80S Ribosome | 1 | 80S Ribosome modulator | Phase 2 | https://conductscience.org/library/genes/2197 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 1 | HMG-CoA reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| IKBKB | Inhibitor of nuclear factor kappa-B kinase subunit beta | 1 | Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor | Phase 2/3 | https://conductscience.org/library/genes/3551 | Drugs and targets |
| KEAP1 | Keap1/Nrf2 | 1 | Keap1/Nrf2 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/9817 | Drugs and targets |
| NFE2L2 | Keap1/Nrf2 | 1 | Keap1/Nrf2 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/4780 | Drugs and targets |
1 to 10 of 94
See all 94 targetsTrials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03019185 | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL | Phase 2/3 | 187 | 2023-10-11 | Alport Syndrome | BARDOXOLONE METHYL | Its record names the disease | ClinicalTrials.gov |
| NCT02855268 | Study of Lademirsen (SAR339375) in Patients With Alport Syndrome | Phase 2 | 43 | 2023-10-23 | Alport Syndrome | LADEMIRSEN | Its record names the disease | ClinicalTrials.gov |
| NCT05448755 | A Study of ELX-02 in Patients With Alport Syndrome | Phase 2 | 3 | 2026-02-24 | Alport Syndrome | ELX-02 | Its record names the disease | ClinicalTrials.gov |
| NCT02378805 | Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome | 800 | Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease, Thin Basement Membrane Disease, Familial Benign Hematuria | FINERENONE, PARICALCITOL, RAMIPRIL, SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov | ||
| NCT05133050 | Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants | Not applicable | 510 | Alport Syndrome | RAMIPRIL | Its record names the disease | ClinicalTrials.gov | |
| NCT06226896 | Effects of Dapagliflozin on Progression of Alport Syndrome | 222 | Alport Syndrome | DAPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT04573920 | Atrasentan in Patients With Proteinuric Glomerular Diseases | Phase 2 | 103 | IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy | ATRASENTAN | Its record names the disease | ClinicalTrials.gov | |
| NCT05003986 | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Phase 2 | 67 | Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome | SPARSENTAN | Its record names the disease | ClinicalTrials.gov | |
| NCT01485978 | Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome | Phase 3 | 66 | Renal Insufficiency, Chronic | RAMIPRIL | Its record names the disease | ClinicalTrials.gov | |
| NCT04937907 | Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) | Phase 2 | 50 | Alport Syndrome, X-Linked | HYDROXYCHLOROQUINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| DB Period: Lademirsen vs DB Period: Placebo: DB Period: Number of Participants Who Developed End Stage Renal Disease (ESRD) | 1 of 29 | 0 of 14 | 43 | NCT02855268 |
Source Trial comparisons
Papers from its trials22
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018965
GET https://conductscience.org/api/diseases/v1/MONDO_0018965/drugs?page=2